A bankruptcy court this week approved the $305 million sale of genetics testing firm 23andMe to a nonprofit organization led by the company's former CEO Anne Wojcicki, the company announced. The ...

We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Regeneron Pharmaceuticals, ...

After the company filed for bankruptcy in March, this week, the sale of 23andMe was completed after previously being approved by a judge.

That means Wojcicki’s nonprofit TTAM Research Institute will purchase “substantially all” of San Francisco-based 23andMe’s assets for $305 million. The transaction — which arrives more than three ...

Our previous report on the Chapter 11 case of 23andMe discussed the Sale Order entered by the Bankruptcy Court on June 27, ...

After a couple of months of non-stop litigation, counsel for the debtor at Paul, Weiss and for the acquirer—a newly formed ...

Me’s privacy ombudsman secured court approval to retain WilmerHale in the DNA testing company’s Chapter 11 case despite an ...

The largest genetic analysis of stuttering has demonstrated a clear genetic basis for the speech disorder, highlighting ...

To qualify for a cybersecurity-related claim, one must be a 23andMe customer between May 1, 2023, and Oct. 1, 2023; have ...

He said it will protect consumer privacy by restricting the sale of genetic data obtained from individuals by biotech ...

Biotech company 23andMe is filing for bankruptcy, prompting concerns over what will happen to its troves of genetic data. In a statement, the company said it is looking to sell “substantially ...

A bankruptcy judge approved the sale of 23andMe's assets and business operations to a nonprofit led by 23andMe’s co-founder and former chief executive, Anne Wojcicki.